Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.
Adolescent
Adult
Aged
Female
Heterozygote
Humans
Hypercalciuria
/ genetics
Male
Middle Aged
Mutation
Pedigree
Prospective Studies
Retrospective Studies
Rickets, Hypophosphatemic
/ genetics
Sodium-Phosphate Cotransporter Proteins, Type IIa
/ genetics
Sodium-Phosphate Cotransporter Proteins, Type IIc
/ genetics
Young Adult
SLC34A
SLC34A1
digenic
hypercalciuria
hypophosphatemia
rickets
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
20
01
2020
accepted:
16
04
2020
pubmed:
21
4
2020
medline:
4
2
2021
entrez:
21
4
2020
Statut:
ppublish
Résumé
Hypophosphatemia and metabolic bone disease are associated with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to biallelic mutations of SLC34A3 encoding the NPT2C sodium-phosphate cotransporter and nephrolithiasis/osteoporosis, hypophosphatemic 1 (NPHLOP1) due to monoallelic mutations in SLC34A1 encoding the NPT2A sodium-phosphate cotransporter. To identify a genetic cause of apparent dominant transmission of HHRH. Retrospective and prospective analysis of clinical and molecular characteristics of patients studied in 2 academic medical centers. We recruited 4 affected and 3 unaffected members of a 4-generation family in which the proband presented with apparent HHRH. We performed clinical examinations, biochemical and radiological analyses, and molecular studies of genomic DNA. The proband and her affected sister and mother carried pathogenic heterozygous mutations in 2 related genes, SLC34A1 (exon 13, c.1535G>A; p.R512H) and SLC34A3 (exon 13, c.1561dupC; L521Pfs*72). The proband and her affected sister inherited both gene mutations from their mother, while their clinically less affected brother, father, and paternal grandmother carried only the SLC34A3 mutation. Renal phosphate-wasting exhibited both a gene dosage-effect and an age-dependent attenuation of severity. We describe a kindred with autosomal dominant hypophosphatemic rickets in which whole exome analysis identified digenic heterozygous mutations in SLC34A1 and SLC34A3. Subjects with both mutations were more severely affected than subjects carrying only one mutation. These findings highlight the challenges of assigning causality to plausible genetic variants in the next generation sequencing era.
Identifiants
pubmed: 32311027
pii: 5822859
doi: 10.1210/clinem/dgaa217
pmc: PMC7448300
pii:
doi:
Substances chimiques
SLC34A1 protein, human
0
SLC34A3 protein, human
0
Sodium-Phosphate Cotransporter Proteins, Type IIa
0
Sodium-Phosphate Cotransporter Proteins, Type IIc
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : K12 DK094723
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK114477
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK112955
Pays : United States
Informations de copyright
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Clin Res Pediatr Endocrinol. 2018 May 29;10(4):343-349
pubmed: 29809158
Clin Chem. 2012 May;58(5):854-68
pubmed: 22371482
Pflugers Arch. 2019 Jan;471(1):15-42
pubmed: 30244375
Am J Hum Genet. 2006 Feb;78(2):193-201
pubmed: 16358215
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32311027
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5372-7
pubmed: 9560283
Genome Biol. 2016 Jan 19;16:269
pubmed: 26781582
N Engl J Med. 2008 Sep 11;359(11):1128-35
pubmed: 18784102
N Engl J Med. 2002 Sep 26;347(13):983-91
pubmed: 12324554
J Med Genet. 2015 Mar;52(3):163-74
pubmed: 25575550
Am J Hum Genet. 2007 Nov;81(5):1084-97
pubmed: 17924348
BMC Pediatr. 2019 Apr 18;19(1):114
pubmed: 30999883
J Am Soc Nephrol. 2015 Mar;26(3):543-51
pubmed: 25296721
Bone. 2017 Apr;97:15-19
pubmed: 27939817
Am J Physiol Renal Physiol. 2009 Apr;296(4):F691-9
pubmed: 19073637
Physiol Rep. 2018 Jun;6(12):e13715
pubmed: 29924459
Science. 2008 Feb 8;319(5864):816-9
pubmed: 18174396
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11470-5
pubmed: 12169661
Endocrinology. 2019 Oct 1;160(10):2204-2214
pubmed: 31237611
J Clin Invest. 2007 Feb;117(2):457-63
pubmed: 17235395
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Am Soc Nephrol. 2008 Sep;19(9):1753-62
pubmed: 18550648
Pflugers Arch. 2019 Jan;471(1):149-163
pubmed: 30109410
Am J Physiol Renal Physiol. 2009 Sep;297(3):F671-8
pubmed: 19570882
J Am Soc Nephrol. 2016 Feb;27(2):604-14
pubmed: 26047794
Lancet. 1975 Aug 16;2(7929):309-10
pubmed: 50513
J Am Soc Nephrol. 2014 Oct;25(10):2366-75
pubmed: 24700880
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Pflugers Arch. 2019 Jan;471(1):83-98
pubmed: 30393837
J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):381-8
pubmed: 17293108
J Med Genet. 2010 Dec;47(12):797-802
pubmed: 19643772
Am J Hum Genet. 2006 Feb;78(2):179-92
pubmed: 16358214
J Clin Endocrinol Metab. 2017 Dec 1;102(12):4604-4614
pubmed: 29029121
Kidney Int. 2018 Jan;93(1):204-213
pubmed: 28893421
Ann Clin Biochem. 1998 Mar;35 ( Pt 2):201-6
pubmed: 9547891
J Clin Endocrinol Metab. 2009 Nov;94(11):4433-8
pubmed: 19820004
N Engl J Med. 1985 Mar 7;312(10):611-7
pubmed: 2983203
Clin Exp Nephrol. 2017 Mar;21(Suppl 1):21-26
pubmed: 27900568
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11957-62
pubmed: 12192091
J Bone Miner Res. 2003 Apr;18(4):644-57
pubmed: 12674325
Nucleic Acids Res. 2016 Jan 4;44(D1):D900-7
pubmed: 26481352
PLoS One. 2012;7(5):e38220
pubmed: 22693602
Clin Nephrol. 1982 Apr;17(4):163-71
pubmed: 7075034
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2501-2507
pubmed: 28453858
Bioinformatics. 2010 Nov 15;26(22):2867-73
pubmed: 20926424
Hum Genet. 2019 Mar;138(3):211-219
pubmed: 30778725